Araris Biotech Closes $24 Million Financing Round


ZURICH, Switzerland, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Araris Biotech AG (“Araris” or “the Company”), a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, today announced the closing of a $24 million financing round, bringing the total funds raised to $40 million to date.

See the original post here:
Araris Biotech Closes $24 Million Financing Round

Related Posts